6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A Systematic Review, Meta-Analysis, and Meta-Regression Evaluating the Efficacy and Mechanisms of Action of Probiotics and Synbiotics in the Prevention of Surgical Site Infections and Surgery-Related Complications

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Intestinal microbiota play an important role in the pathogenesis of surgical site infections (SSIs) and other surgery-related complications (SRCs). Probiotics and synbiotics were found to lower the risk of surgical infections and other surgery-related adverse events. We systematically reviewed the approach based on the administration of probiotics and synbiotics to diminish SSIs/SRCs rates in patients undergoing various surgical treatments and to determine the mechanisms responsible for their effectiveness. A systematic literature search in PubMed/MEDLINE/Cochrane Central Register of Controlled Trials from the inception of databases to June 2018 for trials in patients undergoing surgery supplemented with pre/pro/synbiotics and randomized to the intervention versus placebo/no treatment and reporting on primarily: (i) putative mechanisms of probiotic/symbiotic action, and secondarily (ii) SSIs and SRCs outcomes. Random-effect model meta-analysis and meta-regression analysis of outcomes was done. Thirty-five trials comprising 3028 adult patients were included; interventions were probiotics ( n = 16) and synbiotics ( n = 19 trials). We found that C-reactive protein (CRP) and Interleukin-6 (IL-6) were significantly decreased (SMD: −0.40, 95% CI [−0.79, −0.02], p = 0.041; SMD: −0.41, 95% CI [−0.70, −0.02], p = 0.006, respectively) while concentration of acetic, butyric, and propionic acids were elevated in patients supplemented with probiotics (SMD: 1.78, 95% CI [0.80, 2.76], p = 0.0004; SMD: 0.67, 95% CI [0.37, −0.97], p = 0.00001; SMD: 0.46, 95% CI [0.18, 0.73], p = 0.001, respectively). Meta-analysis confirmed that pro- and synbiotics supplementation was associated with significant reduction in the incidence of SRCs including abdominal distention, diarrhea, pneumonia, sepsis, surgery site infection (including superficial incisional), and urinary tract infection, as well as the duration of antibiotic therapy, duration of postoperative pyrexia, time of fluid introduction, solid diet, and duration of hospital stay ( p < 0.05). Probiotics and synbiotics administration counteract SSIs/SRCs via modulating gut-immune response and production of short chain fatty acids.

          Related collections

          Most cited references84

          • Record: found
          • Abstract: found
          • Article: not found

          Potential beneficial effects of butyrate in intestinal and extraintestinal diseases

          The multiple beneficial effects on human health of the short-chain fatty acid butyrate, synthesized from non-absorbed carbohydrate by colonic microbiota, are well documented. At the intestinal level, butyrate plays a regulatory role on the transepithelial fluid transport, ameliorates mucosal inflammation and oxidative status, reinforces the epithelial defense barrier, and modulates visceral sensitivity and intestinal motility. In addition, a growing number of studies have stressed the role of butyrate in the prevention and inhibition of colorectal cancer. At the extraintestinal level, butyrate exerts potentially useful effects on many conditions, including hemoglobinopathies, genetic metabolic diseases, hypercholesterolemia, insulin resistance, and ischemic stroke. The mechanisms of action of butyrate are different; many of these are related to its potent regulatory effects on gene expression. These data suggest a wide spectrum of positive effects exerted by butyrate, with a high potential for a therapeutic use in human medicine.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            A gut-vascular barrier controls the systemic dissemination of bacteria.

            In healthy individuals, the intestinal microbiota cannot access the liver, spleen, or other peripheral tissues. Some pathogenic bacteria can reach these sites, however, and can induce a systemic immune response. How such compartmentalization is achieved is unknown. We identify a gut-vascular barrier (GVB) in mice and humans that controls the translocation of antigens into the blood stream and prohibits entry of the microbiota. Salmonella typhimurium can penetrate the GVB in a manner dependent on its pathogenicity island (Spi) 2-encoded type III secretion system and on decreased β-catenin-dependent signaling in gut endothelial cells. The GVB is modified in celiac disease patients with elevated serum transaminases, which indicates that GVB dismantling may be responsible for liver damage in these patients. Understanding the GVB may provide new insights into the regulation of the gut-liver axis.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              American College of Surgeons and Surgical Infection Society: Surgical Site Infection Guidelines, 2016 Update.

                Bookmark

                Author and article information

                Journal
                J Clin Med
                J Clin Med
                jcm
                Journal of Clinical Medicine
                MDPI
                2077-0383
                16 December 2018
                December 2018
                : 7
                : 12
                : 556
                Affiliations
                [1 ]Department of Biochemistry and Human Nutrition, Pomeranian Medical University, Szczecin 71-460, Poland; karzyd@ 123456pum.edu.pl (K.S.-Ż.); sanprobi@ 123456sanprobi.pl (I.Ł.); dmaciejewska.pum@ 123456gmail.com (D.M.)
                [2 ]Department of Clinical and Molecular Biochemistry, Pomeranian Medical University, Szczecin 70-111, Poland; mariush@ 123456pum.edu.pl
                [3 ]Division of Gastroenterology, Hepatology, and Nutrition, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA; Luis.Lara@ 123456osumc.edu
                [4 ]Centre for Liver & Digestive Disorders, Royal Infirmary of Edinburgh, Edinburgh EH16 4SA, UK; akoulaouzidis@ 123456hotmail.com
                [5 ]Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin 13353, Germany; agata.misera@ 123456charite.de
                [6 ]Department of Gastroenterology, Pomeranian Medical University, Szczecin 71-252, Poland
                Author notes
                [* ]Correspondence: marlicz@ 123456hotmail.com ; Tel.: +48-91-425-3231
                Author information
                https://orcid.org/0000-0002-3430-9079
                https://orcid.org/0000-0002-2248-489X
                https://orcid.org/0000-0002-2649-5967
                Article
                jcm-07-00556
                10.3390/jcm7120556
                6307089
                30558358
                2a818310-88bf-4081-adda-3427f2c8e46c
                © 2018 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 10 November 2018
                : 13 December 2018
                Categories
                Article

                surgical site infections (ssis),probiotics,prebiotics,synbiotics,surgery,adverse events,microbiota,meta-analysis,systematic review

                Comments

                Comment on this article